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ABSTRACT
The effectiveness of a prescription drug monitoring program in coordination with
a prescription opioid recidivism program was examined at a semi-rural community
hospital. Patients were identified by a multi-disciplinary committee to be at-risk for
opioid misuse or abuse, and were denied prescription opioids. Patients were considered
eligible for the program if they had over 12 emergency department visits in the previous
12 months, or 6 visits in the previous 6 months, depending on how long the hospital had
records on a patient. Patients who were placed in the prescription opioid recidivism
program could not receive opioids at this hospital. The number of visits these patients had
in subsequent 12 month periods was examined. Of the 298 patients enrolled in the
recidivism program, 95% of them would see a reduction in the number of emergency
department visits made in the 12 months following enrollment in the recidivism program.
This resulted in a savings of $2.5 million in operations for the hospital. The use of
prescription drug monitoring programs to combat the opioid epidemic shows potential as
a solution, but needs to be examined further to determine how effective these systems can
be.
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Introduction

The negative side effects and consequences of popular opioid medications are a
grave concern of the general population of the United States of America. Recently, the
amount of opioids that are being prescribed in the United States is skyrocketing and a
greater percentage of the population is being effected by the drug (Jones, Mack, &
Paulozzi, 2010). The United States alone consumes over three-fourths of the world’s
opioids (American Society of Interventional Pain Physicians, n.d.). In turn, the amount of
misuse, abuse, and deaths coming from opioid use is also on the rise. Locally, New
Mexico had the 8th highest drug overdose mortality rate in the country at 25.3, and a
nearly a third of these deaths occur to the under 18 population in 2015 (Center for
Disease Control, 2017). In 2014, 40 percent of the overdose deaths were attributed to
prescription opioid medications (New Mexico Epidemiology, 2017).
In addition to this, individuals who are seeking an opioid prescription are creating
inefficiencies in hospitals, clinics, and doctor offices around the country. Emergency care
providers are visited by these opioid-seeking individuals more often than other
practitioners (Smith, et al., 2015). With the nature of emergency medicine, it can be
difficult for these providers to accurately provide care to patients. For example, anyone
can come through the doors, and they are legally obligated to receive treatment, a factor
not seen in primary care. Because of this, emergency practitioners are required to use
their time and ability to provide treatment for the patients that enter the emergency
department (ED). However, receiving treatment may not be the goal of all patients.
Whether conscious of it or not, patients engage in health care with a certain expectation,
and the failure of the provider to meet these expectations can have negative effects on the
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patient, and their perceptions of the providers (Lateef, 2011). Some patients are
exclusively looking for an opioid prescription and will try until they accomplish their
goal and receive the desired prescription. This is a behavior known as doctor shopping
(Sansone & Sansone, 2012). If opioid-seeking patients continue to burden the health care
system, and detract from the care of other patients, the opioid epidemic will cause further
negative economic and health issues. By recognizing these issues early, and acting to
eliminate them, administrators can create policies that rid their organizations of
inefficiencies, while also being a step ahead when it comes to regulations.
For example, without proper systems in place, patients can go from doctor to
doctor, hospital to hospital, until they are given the prescription they are looking for.
Every doctor-shopping visit reduces the benefit other patients, who have actual medical
needs, can experience and gain from their providers (Norton et al., 2011). However,
systems can be put in place to combat doctor shopping and opioid seekers. One of these
systems used to decrease doctor shopping, among other things, involves using electronic
health records and prescription drug monitoring programs.
Prescription drug monitoring programs (PDMPs) can inform doctors,
administrators, pharmacists, review boards, and other entities on the amount of opioids
that are being prescribed, as well as when they were prescribed (John Hopkins
Bloomberg School of Public Health 2015). Another system that can be implemented
would be a Health Information Exchange (HIE). HIEs can be used to increase the
effectiveness of treatment by having a thorough and timely sharing of records. The
benefit of HIEs is they can share information across hospitals and clinics that have no
affiliations (Furukawa, Patel, Charles, Swain, & Mostashari, 2013). This information can
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inform providers that individuals have already been prescribed a medication and should
not be in need of further medication at the current time. Also, these programs can inform
the prescribing provider that the patient may need substance abuse treatment due to the
number of visits that are deemed opioid seeking (John Hopkins Bloomberg School of
Public Health 2015). Gathering, centralizing, and disseminating this information, can be
used to determine if these patients are displaying behaviors that are associated with
opioid abuse, doctor shopping, and drug addiction. Also, the monitoring programs can
identify doctors that are overly liberal with their prescription pads. By using electronic
health records, this prescription information can be kept up-to-date and utilized in real
time. This is a benefit to hospitals as they can better the behaviors of their doctors and
eliminate unnecessary and expensive visits.
However, PDMPs were accessed in fewer than a quarter of the cases in which an
opioid was prescribed, which negates the possible benefits of the systems (John Hopkins
Bloomberg School of Public Health 2015). This an example of administrators not using
existing systems to eliminate waste and improve health outcomes for patients of their
organizations. One of the complaints on the PDMPs is the amount of time the programs
take to access and utilize. Given these programs are most useful in the emergency setting,
where time is more limited than compared to primary care visits, it is essential for
administrators to properly create systems that allow the efficient use of PDMPs and
electronic health records.
Research question: What effect does a PDMP have on the number of unnecessary
visits to a hospital’s emergency department?

ANALYZING PDMPS AND OPIOID USE

4

Literature Review
History of Opioids
In Ancient Greece, many pain management practices stemmed from the work of
physician Galen. Galen makes reference to “Olympic Victor’s Dark Ointment” which he
stated could be used for the treatment of pain and swelling (Harrison, Hansen, & Bartels,
2012). This ointment was opioid based and would form a patch when applied to the skin.
This pain intervention has been shown to be effective in modern times and could provide
information into improving the current methods of pain management (Harrison, et al.,
2012). In fact, because the study showing the effectiveness of the patches was completed
on mice, and the human body consists of a greater amount of hair follicles than a mouse,
the effects could be greater for humans. When applied locally, modern patches have
shown to have a pain-relieving effect, and provide a more controlled and direct mean of
dosing (Harrison, et al., 2012). Not only have opioids been shown to be effective in the
reduction of pain, but they can also be an effective tool in the wound healing process.
If the delivery of morphine, or other opioids can be improved, opioids could
become a more comprehensive method to the treatment of both pain and wound healing
(Harrison, et al., 2012). Also, the localization of the patch could improve the
effectiveness of the medication, allowing for smaller doses, which would likely reduce
the motivation of some opioid seekers. Hospital administrators should be wearied of this
finding as the required use of patches, when possible, could reduce the number of
unnecessary visits their facility experiences. Also, because the patches contain a
decreased amount of medicine, there would be less cost savings as less of the drug is
being purchased.
Throughout time, innovations and new application of opioids have been explored.
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In the sixteenth century, laudanum, which is an opium distributed in an alcoholic
solution, was used as a painkiller. Laudanum was introduced by Paracelsus and the pills
were called “Stones of Immortality”, and even though they were prescribed as painkillers,
it is clear the euphoric effects have always been recognized (Public Broadcasting Service,
1998). This aligns with the origins of the plant, as the first mention of opioids comes
from the Sumerians who referred to plant as “Hul Gil”, or the “joy plant” (Brownstein,
1993; Public Broadcasting Service, 1998). Then, the first-time morphine was extracted
from opium, was in the early nineteenth century (Drug Free World, n.d.; Brownstein,
1993). Morphine was used heavily as a pain killer during the Civil War, with the result of
many soldiers becoming addicted to the medication. A few decades later, Jean-Pierre
Robiquet isolated codeine from opium in an attempt to replace raw opium in medicine
(Drug Free World, n.d.).
Today, codeine is mostly used as a cough remedy prepared as a liquid medicine. By
the early nineteenth century, the British dependence of opioids was at an all-time high
and the recreational use was on the rise. There was even an “Opium War” in 1839 as the
British sent warships to the coast of China, this after China attempted to reduce the
amount of opioids on the market. In 1874, in an attempt to find a less addictive form of
morphine, chemists created heroin (Drug Free World, n.d.; Brownstein, 1993). This drug
would end up being twice as powerful as morphine, and the number of individuals
addicted to this substance would soon rise (Brownstein, 1993). In response to the rising
levels of opioid use, abuse, and addiction, the United States Congress banned opium in
1905 (Drug Free World, n.d.).
In a similar attempt as the chemists who created heroin, German scientists Max
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Bockmuhl and Gustav Ehrhart were looking for a drug with less addiction potential that
could be used easily during surgery. This led to the creation of methadone, which is
believed to be even more addictive than either of the previously existing morphine or
heroin (Drug Free World, n.d.; Brownstein, 1993). New opioid medication has continued
to be developed, as the United States saw the creation of Vicodin, OxyCotin, and
Percocet between 1984 and 1999 (Drug Free World, n.d.). These are all synthetic opiates
that create a response similar to how the body responds to the release of its own natural
pain killers. While the prescription opioid market was seeing innovation and increases in
sales, the illegal opium market was also on the rise. This was evidenced as Southeast
Asia was producing 2,500 tons every year (Drug Free World, n.d.). With opioids, in
many forms, being a part of human society and history it is clear we have a reliance on
the chemical, and it does not appear to be diminishing. Given the mishaps in the attempt
to find an alternative method of administration, it is clear we do not understand the
chemical either. This point is made even clearer when examining the misuse and abuse
humans have engaged in with the drug for generations. With an abundance on the
varieties of opioids, and a plethora of patients, the amount of strain opioids create on the
health care system has to be examined.
Opioids in Modern Medicine
While the chemical has been around for centuries, the distribution and use of
opioids are creating original problems in the modern society we live in. Visits to the
emergency department are more expensive for the patient, as well as the provider. The
cost of the average primary care visit for a new, and uninsured, patient is $160 (Saloner,
Polsky, Kenney, Hempstead, & Rhodes, 2015). In comparison, the median visit to an
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emergency department will cost $1,233 (Caldwell, Srebotnjak, Wang, & Hsia, 2013).
There are many programs and initiatives created by providers to help citizens understand
what injuries, or complications, should be brought to an emergency department, and what
ailments are not serious enough for this level of care. However, it has been determined
that around 37% of all emergency department visits are unnecessary and non-urgent
(Uscher-Pines, Pines, Kellerman, Gillen, & Mehrotra, 2013). These unnecessary visits
can lead to issues in the healthcare system including, but not limited to, excessive testing,
treatment, and spending (Uscher-Pines, et al., 2013). This misuse of the health care
system can also lead to a fracturing of the patient-provider relationship (Uscher-Pines, et
al., 2013). Administrators need to be aware of these issues as they can negatively impact
the care being provided by the hospital, as well as the reputation of the provider.
One cause of these unnecessary visits are those deemed to be opioid-seeking visits.
Opioid seeking can be operationalized as a pattern of behavior centering around the
search and obtainment of opioids when they are not readily available (Fattore, Fadda,
Antinori, & Fratta, 2014). Emergency medicine providers are visited by opioid-seeking
individuals more often than other health care providers, and are also the leading
prescriber of opioid medication (Smith et al., 2015). These visits from the opioid-using
population have been described as being harder to treat, as the patients need more support
from the provider, in a number of ways (Greenfield, Ownes, Lee, 2014). Total costs of
medical visits were significantly higher for visits deemed to be opioid abuse or opioidseeking related ($14,537) than matched controls ($8,663) (McAdam-Marx, Roland,
Cleveland, & Oderda, 2010). Not only are these visits more expensive, but they are also
occurring more often than in past.
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Providers who work in emergency medicine have patients with pain issues
stemming from a variety of etiologies. The initiation of pain treatment often begins
without an established doctor-patient relationship, which is a benefit to successful pain
interventions, and treatment overall (Wells, Pasero, & McCaffery, 2008). For example,
when visiting an existing primary care provider, the physician will have records of past
visits, as well as the results of past treatments and medications, whereas the emergency
care physician may not know the patient’s name when they initiate care. Because the
primary care physician has a greater amount of information they are more likely to create
an effective treatment plan while the emergency care physician may have to treat based
on assumptions. Also, the emergency care setting can often consist of visits with
inconsistent care as there could be patients with more pressing needs and concerns, or the
provider may rush the patient out as they need the bed for another patient who is in a
more critical condition (Hoppe, Houghland, Yaron, & Heard, 2013). This can lead to
some ailments going untreated or under cared for. Patients and physicians may have
different expectations for pain control. As mentioned, this may lead to a fracturing of the
patient-provider relationship. Because opioids are an essential aspect of acute and chronic
analgesia, physicians must balance the risk of possible misuse, abuse, and diversion, with
the need for adequate pain relief (Hoppe, et al., 2013). Some studies have called for a
more inhibited, or aggressive, approach to the prescription of opioid medication in the
emergency department setting, and this seems to match the trend of opioid prescriptions
(Wilson & Pendleton, 1989).
Opioid epidemic in the United States
While many of the negative aspects of the opioid epidemic are being seen in the
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emergency department, the issue extends far past the walls of hospitals. In 2012, nearly 5
million individuals in the United States used prescription opioids in the prior month
(Greenfield, et al., 2014). From 1995 through 2008 the number of opioid-seeking visits
has increased by over 600 percent (Manchikanti, Fellows, Ailinani, & Pampati, 2010). In
addition, the number of deaths resulting from an overdose of prescription opioid
medication saw a near 400 percent increase (4,041 to 16,651) between the years of 1999
and 2010 (Jones, et al., 2010). In 2007, the number of deaths attributed to the use of
opioids, about 35,000, surpassed the number of deaths stemming from motor vehicle
accidents (Nolan & Amico, 2016). Today, the amount of drug overdose deaths attributed
to opioids, nearly 19,000, has surpassed the number of heroin overdoses, 10,574
(Sherman, 2016). In the United States there is an estimated 120 drug overdose deaths
every day, with the majority being attributed to the many forms of opioids (Rudd,
Aleshire, Zibbell, & Gladden, 2016). While the epidemic has spread throughout the
nation, in 2012 there were twelve states in the United States that had more opioid
prescriptions than it did citizens (Nolan & Amico 2016). One of these states was New
Mexico (Nolan & Amico 2016).
New Mexico, one of the states that leads the country in drug overdose deaths, saw
489 overdose deaths in 2012. Of these causalities, 49.3 percent of the deaths were
attributed to opioid pain relievers (Levy et al., 2016). The number of overdoes increased
to 547 in 2014, which is greater than the number of deaths resulting from firearm deaths,
motor vehicle deaths, and falling deaths (Kaltenbach, 2016). The state of New Mexico
has the highest drug overdose death rate for most of the past twenty years, and is
typically twice the national average (Kaltenbach, 2016). The majority of these deaths are
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opioid related, and the state is also experiencing a similar increase in the number of
overdoses.
From 2000-2014, the number of opioid related deaths rose 95%, resulting in one
death every day being attributed to an opioid-involved overdose (Kaltenbach, 2016). The
majority of these deaths, 60%, involved prescription drugs, and no dual consumption
with heroin. Particular areas in New Mexico, such as Taos County, Española, and the
surrounding area of Northern New Mexico, have seen overdose rates that are more than
4.5 times the national average, as they see 67.7 overdose deaths per 100,000 people,
compared to the national average of 14.7 per 100,000 (Centers for Disease Control and
Prevention, n.d.).
This issue is not exclusive to adults, as minors are being exposed to the opioid
epidemic as well. New Mexico youth report increased rates of non-medical prescription
opioid use, compared to those over age of 25. The rate at which New Mexico high school
students use opioids, and illegal drugs, is much higher than when compared to other
students around the country (Centers for Disease Control and Prevention, n.d.). In
addition, these minors have a higher usage rate of heroin, and contribute to heroin
overdoses at a larger rate than other states (Greenfield, et al., 2014). This could signal a
gateway effect, which would increase the need for stricter regulations. The increase in
prescribing opioids has been constant across all ages, as the rate of young adults who
have been prescribed opioids has rose from 4 to 10 percent between 1994 and 2007
(Fortuna, Robbins, Caiola, Joynt, & Halterman, 2010). Of New Mexicans who entered
treatment programs in 2011, a third of these individuals were under the age of 25 (U.S.
Department of Health and Human Services, 2012). This issue of opioid overdoses is not
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particular to New Mexico.
The United States as a whole is seeing statistics related to opioid use and
prescribing behaviors increase. From 1999 through 2014, there were a total of 165,000
deaths that were attributed to overdosing on prescription opioid medications in the United
States (Houry & Baldwin, 2016). During the same time period, the amount of opioid
medication that was prescribed quadrupled, while there was no increase in the amount of
pain being reported (Manchikanti, et al., 2010; Houry & Baldwin, 2016). With the
increase in the amount of opioid medication prescribed, it is also likely to assume the rate
of opioid abuse, diversion, and overdoses would have a similar increase (Fishman,
Papazian, Gonzalez, Riches, & Gilson, 2004). In fact, overdoses, and opioid abuse, have
steadily been rising (Sullivan et al., 2008). While it appears the prescribing of opioids can
lead to negative consequences, so too can the denial of prescription opioid medications.
Individuals who reported being denied opiates also reported higher levels of risk
behaviors centered around opioids including daily use, engaging in illegal activities in
order to obtain opioids, or the selling of opioids. These individuals also reported
engaging in opioid misuse earlier in their lives than others (Fibbi, Silva, Johnson, Langer,
& Lankenau, 2012). Those denied the desired medication also reported being prescribed
opioids at a time prior to being denied. Reasons for a patient being denied opiates range
from lack of insurance, access to the drug limited by an authority figure, and being
identified as a drug abuser by the physician (Fibbi, et al., 2012). Individuals with a
history of substance abuse or drug treatment, or those who reported injection drug use,
were more likely to be denied prescriptions for their pain (Breitbart et al., 1997). Those
with substance abuse histories were also doubted by physicians in regards to the veracity

ANALYZING PDMPS AND OPIOID USE

12

of their reported pain levels (Fibbi, et al., 2012).
This lends credence to the theory of having a more aggressive approach to
prescribing opioids, as individuals may be experiencing high levels of pain, and having a
conservative approach to prescribing opioids may lead to the patient seek pain relief
elsewhere. Untreated pain problems may lead to the misuse and abuse of illicit and
prescription drugs (Novak, Herman-Stahl, Flannery, & Zimmerman, 2009). Upon being
denied their opioid prescription, many patients sought pain relief elsewhere, either
acquiring prescription opioids from another source, whether that be a friend, or a stranger
(Fibbi et al., 2012). While less likely, these patients may seek out heroin as an alternative
solution (Fibbi, et al., 2012).
While the number of visits, prescriptions, and adverse effects continue to rise,
questions remain in regards to the efficacy of opioids being used to treat chronic pain
(Trescot, et al., 2008; Cantrill et al., 2012). Studies have shown these medications can be
effective in treating non-cancer chronic pain, but these studies are short-term and have no
efficacy in determining if the same effectiveness is seen over longer periods of time
(Trescot, et al., 2008). Also, there is little to no information on how these medications
correlate with abuse or addiction, which is more likely for patients receiving opioids as a
long-term solution (Cantrill et al., 2012). One study conducted by Shah, Hayes, and
Martin, show certain characteristics of prescriptions have a greater chance of the patient
being prescribed the medication becoming addicted (2017). The characteristics were
observed on first time opioid patients, who were commercially insured, cancer-free, and
opioid naive. The factors of the prescriptions included five and thirty days of opioid
therapy, there being a second opioid prescription event, the cumulative dose being 700
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morphine milligrams, and prescriptions with a ten and 30-day supply (Shah, et al., 2017).
One out of every seven patients in actor pain treatment who were given a second
prescription, or used a refill, remained on opioids for at least a year (Shah, et al., 2017).
These findings are supported by a study from Oregon in which the researchers
found patients who received two prescription refills, or reached a cumulative dose
between 400-799 morphine milligrams, were 2.3 and 3 times more likely to develop
chronic opioid use behaviors, respectively (Deyo et al., 2016). This information is
essential for administrators to be aware of as policies or guidelines could be formed to
limit the amount of opioids or number of prescriptions the physicians write for patients.
Thresholds, or benchmark indicators, can be useful for administrators in general in
identifying issues or in creating organization-wide standards or expectations.
However, because opioids are proven to be effective in treating pain related to
cancer and cancer treatments, and acute pain, there is support to allow opioids to be
prescribed to all, with less regard to the possibility of addiction (Manchikanti, et al.,
2010). This, in combination with advocacy groups pointing to the deleterious effects
chronic pain can cause as a reason for the unlimited use of opioids, has led to opioids
having a significant increase in availability and use of these medications (Noble et al.,
2007). Furthermore, the increase in utilization has led to an increase in production, which
has increased the price of opioid medication (Trescot, et al., 2008).
With this increase in all aspects of the opioid process, the Center for Disease
Control (CDC) created a guideline for the prescribing of opioids with the intent of
treating pain. The recommendations include which opioids to prescribe, as well as the
duration the patients should be allowed to have these medications (Dowell, Haegerich, &
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Chou, 2016). The reason for the guidelines is that the CDC has also determined the use of
opioids in America has reached the level of being an epidemic (Sherman, 2016). This is
backed by a sentiment from The New York Times which describes opioid addiction as
“America’s 50-state epidemic” as well as public health officials who call this epidemic
the “worst drug crisis in American history” (Seelye, 2017). In addition to the CDC
guidelines, the New Mexico Board of Pharmacy has also created initiatives and programs
in an attempt to reduce the amount of opioids that are being prescribed, used, and
diverted.
The state of New Mexico created the New Mexico Prescription Monitoring
Program (NMPMP) which compiles prescription and dispensing information in regards to
Schedule II-V controlled substances, which includes prescription opioid medication, but
not heroin (New Mexico Board of Pharmacy Prescription Monitoring Program, n.d.). The
CDC guidelines and the NMPMP can be beneficial to administrators who can influence
the actions of the prescribing physicians. By following the guidelines and utilizing the
NMPMP administrators can easily create new policies and regulations within their
organizations without having to use significant resources in the research and design of the
policies. However, this can also force administrators to create policies and initiatives they
are not prepared to act on. Due to this, it is important for administrators in all industries
to be aware of possible regulations or oversights that may be enacted or altered. By being
proactive and implementing innovative and forward-thinking programs, these concerns
can be avoided. This is especially true for venues that have the amount of regulation and
importance, such as emergency departments.
With 42 percent of visits to emergency departments being attributed to pain, the ED
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could be an efficient and effective venue for reducing and preventing the amount of
opioid related overdoses, while also reducing the strain these visits create on the health
care system (Cantrill et al., 2012; Noble et al., 2007).
Interventions
Drug monitoring programs have been identified as an essential and useful tool for

providers to identify patients with a need for addiction services (Hildebran et al., 2014).
These programs can also be effective in early identification of abuse and in the
prevention of diversion (Hildebran et al., 2014). However, it has been shown the use of
these programs in emergency departments are lower than in primary care, or other
settings. It is also easier for primary care providers to utilize the PDMPs, as they are
aware of who they be providing care for, and when, with some exceptions. With the
majority of opioid related visits occurring in the emergency departments, it is important
for the PDMPs to be readily accessible as these providers do not know who is coming
through their doors, or when (Hildebran, et al., 2014). Also, emergency medicine
providers have been shown to underestimate the amount of opioids they prescribe
(Michael, Babu, Androski, & Reznek, 2016). By utilizing PDMPs, emergency care
providers will be better able to decide whether there is an appropriate need for the
prescription of opioid medications. Also, administrators will also be able to better track
and observe the prescribing habits of their physicians.
In addition to being able to better recognize a patient who is not in need of an
opioid prescription due to past behaviors, or current and recent prescriptions, PDMPs
have direct benefits for providers who implement the system. These monitoring programs
have been shown to decrease the amount of opioid prescriptions, overdose
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hospitalizations related to opioid medications, visits attributed to opioid seeking, and
prescription opioid deaths (John Hopkins Bloomberg School of Public Health, 2015).
These are all outcomes administrators should be looking to eliminate and, through the use
of PDMPs, administrators can quantifiably measure the difference the programs are
making in their organizations. PDMPs can also be beneficial to organizations and
administrators outside of hospitals and emergency departments. The accurate collection
of prescriptions can create benefits and efficiencies for third-party healthcare payers and
pharmacy benefit managers. These entities can use the given information to restrict highrisk individuals to receive care from only one doctor, which can benefit patient health and
safety, while also reducing the number of unnecessary visits attributed to doctor shopping
(John Hopkins Bloomberg School of Public Health, 2015). These programs can also
provide an additional level of oversight from licensing boards, who can identify which
clinicians, physicians, or facilities are prescribing at higher than average rate. Finally,
public health agencies can use the data to identify high risk areas and populations, while
law enforcement can use it to identify those who are high-risk or likely drug diverters
(John Hopkins Bloomberg School of Public Health, 2015).
In 2005, the National All Schedules Prescription Electronic Reporting Act was
established, in order for each state to support a controlled substance monitoring program.
The objective of this Act is intended to give physicians a tool to aid in both prescribing
controlled substances and identification of illicit fraud and abuse (Manchikanti,
Whitfield, & Pallone, 2005). The goal of a PDMP is to provide a balanced approach to
protect public safety and public health while supporting legitimate medical practice
(Hoppe, et al., 2013). Also, the use of PDMPs should lead to a decrease in the amount of
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inappropriate prescriptions, while providing adequate pain management with the use of
appropriate prescriptions (Hoppe, et al., 2013). The appropriate use of these PDMPs
should increase the level of care provided by the hospitals if implemented by
administration. Considering an increased level of care is likely to improve the reputation
of the hospital, these PDMPs should be implemented and utilized whenever possible.
These programs have also proven to have an impact on the opioid epidemic in a positive
manner (Hoppe, et al., 2013). However, as previously mentioned, because the PDMPs
were used less in emergency care than other settings, and emergency care has the highest
number of opioid seekers, it is unclear how effective this program was specifically in the
emergency care setting.
The objective of the recidivism program was to determine if a novel, multidepartmental, coordinated intervention program focused on high-ED-utilizing, opioidseeking patients could reduce the number of visits to the ED at 12 months (Ketcham, et
al., 2014). In addition to this, I am evaluating how this program will have an impact on
administrators and how they can mindfully create, develop, and initiate programs in order
to have a significant impact, while also creating more efficient processes.
Other possible interventions include practices that attempt to stop the pain at the
source, rehabilitation, or other methods rather than attempting to mask the pain. These
methods can range from physical therapy, massage therapy, chiropractic realignment, and
also acupuncture. Even though acupuncture is controversial in Western medicine, studies
have shown it can be an effective treatment method.
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Methods

In 2012, the prescription opioid recidivism program at the previously mentioned
semi-rural, non-academic, community hospital was initiated. While not involved in the
creation of the project, or in the initial data analysis, I have been brought on to examine
the theory and practice of how administrators can implement interventions that have a
positive impact on not only the operations of the organization, the employees of the
organization, but also the customers of the organization. In this particular case, I will be
examining how the implementation of a PDMP in the emergency department can reduce
the impact of recidivism linked to patients with opioid abuse concerns.
This prescription opioid recidivism program hopes to identify individuals who
place the greatest strain on the health care system, and also those who may be the most in
need of an intervention program. The prescription opioid recidivism program was
designed to be a quasi-experimental, open, prospective translational cohort study
(Ketcham et al., 2014). The hospital and physician leading the program have selected a
quasi-experiment for a number of reasons. First, it would be unethical to utilize a control
group in this setting. The control group would either be made of individuals who were
identified as at risk, and then received no assistance to combat their opioid-seeing
behaviors. Also, if the hospital or physicians involved with the recidivism program were
to randomly select individuals in the community, or those who visit the hospital, there
would be no guarantee the population would be representative of the number of opioidseeking individuals that exist in the community. While this design does decrease the
external validity of the program, the design also allows for the population being studied
to receive the greatest benefit. With the prescription opioid recidivism program
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possessing a cohort element, I am hopeful I will able to easily identify factors that could
lead to improved success in the recidivism program. For example, if cohorts that begin
later in the study have more significant, and positive, behavior changes, it is reasonable to
assume the providers have improved their process and skill in regards to this program.
This was not a factor examined by the practitioners involved in the recidivism program.
The setting for the study was in a semi-rural, non-academic, community/county
hospital. The emergency department at this hospital sees over 50,000 patients annually
(Ketcham, et al., 2014). Subjects that made up the population study were both adults and
adolescent patients who had been identified, with a high level of certainty, to use the
emergency department at a high rate for opioid-seeking purposes. These individuals are a
part of the population that has been identified as placing significant strain on the health
care system, particularly in emergency departments similar to this one.
In this prescription opioid recidivism program, a high rate of emergency department
utilization was defined as having greater than twelve visits in a year, or having six visits
in the prior six months (Ketcham, et al., 2014). In addition to exceeding this visit
threshold, patients that were referred by a friend or family member, or another health care
professional, were considered for enrollment in the recidivism program. However, these
individuals would be subject to the same vetting process as individuals identified through
the examination of health records. Upon identification of a patient being at-risk, patients
were systematically reviewed by an impartial, multi-disciplinary committee; known as
the Opioid Recidivism Program Selection Committee. This method of selection differs
from the selection process in previous studies.
A study conducted in Baltimore that did not use the snowball method, a technique
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where interviewers ask their subjects for other individuals to interview, and instead used
a criterion-based selection method. This study found no significant differences in the
ages, genders, marital statuses, or years of education of patients who were identified as
opioid seeking prescription (Gwin Mitchell et al., 2009). In other words, everyone who
entered the program with the snowball method were similar. This could signal that the
snowball method is not a valid method for addiction studies and may not provide a
representative sample (Rounsaville & Kleber, 1985). By avoiding the pure snowball
method, and using a targeted method, the recidivism program was, and will be, able to
recruit patients who meet the criteria for opioid seeking, or opioid abuse, behavior but
were not necessarily connected to other individuals identified as at risk. However, by still
being open to recommendations from others, the recidivism program will benefit from
being able to identify at-risk patients that may not be on the radar of this particular
hospital, or the care providers of the hospital.
This use of targeted sampling could be subject to biases from the selection
committee members who may be looking for characteristics that are not necessarily
indicative of opioid abuse or opioid seeing behavior. However, the practitioners leading
the recidivism program established guidelines, and a criterion for admittance, in an effort
to remove any factors that could lead to admittance for those not truly qualified for
treatment. More importantly, the selection process of the recidivism program utilizes
methods that will remove factors that would prohibit or exclude patients in need of
treatment. With the targeted method, and being open to recommendations, the recidivism
program utilizes positive aspects of previous studies, but is not limited to a certain social
network.
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The selection committee was designed to be multi-departmental so every aspect of
the patients’ health records could be appropriately understood. This led to the committee
being represented by individuals from departments such as the emergency department,
nursing, pharmacy, and administration, as well as representatives from private practice
offices associated with the hospital. The utilization of more than one trained and educated
individual, in order to determine the validity of an opioid prescription, has been validated
in previous studies (Hoppe, et al., 2013).
With members of the selection committee all coming from different areas of
expertise, it was essential for these individuals to receive as much information about the
patients who were identified as at-risk. Because of this, a greater amount of information
than the individuals’ medical charts at the local hospital, or hospitals, were considered. In
addition to the patients’ hospital records being reviewed, the selection committee also
examined emergency department, laboratory, and state pharmacy board records. After a
review of the information, the selection committee was to decide if the individual’s
behaviors were reflective of opioid abuse or opioid-seeking behaviors.
The selection committee had to be in consensus on any decision made about a
patient’s enrollment (Ketcham, et al., 2014). If classified by the committee to be a patient
who represented opioid abuse or opioid seeking behaviors, patients were enrolled in the
recidivism program. This program prohibited the prescription of opioids for these patients
whether they were under hospital care, or leaving the premises. Patients were notified, by
mail, that they had been enrolled in this opioid recidivism program. Patients also received
information on the program upon their first visit to the hospital following admittance to
the program. Also, all enrolled patients were identified as being in the recidivism
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program through an icon on the electronic medical record (EMR) tracking board at the
hospital. Due to the large number of patients identified as possible opioid abusing or
opioid-seeking patients, the committee created a number of cohorts of patients who were
enrolled in the program (Ketcham, et al., 2014).
Physician and nursing staff were trained and educated about the recidivism program
at outset, and informed not to administer opioids to icon-bearing patients unless
circumstances were extenuating. This recidivism program defined extenuating
circumstances to be newly documented severe trauma. In addition, opioid prescriptions
were not to be given to these individuals upon their release from care. The emergency
department utilization rate for members enrolled in the recidivism program was
continually updated via the ED electronic medical record dashboard. The primary
outcome measure was the number of visits over 12 months pre- and post-intervention
made by individuals placed in the recidivism program. Depending on when the patient
was placed into the recidivism program, and when their cohort began, there could be 24month post-intervention data for that particular patient.
In this study all visits to the emergency department were considered to be equal,
and there was no coding or distinguishing between visit that were believed to be
legitimate, and those attributed to opioid seeking behaviors. From March 2012 through
February 2013, the Opioid Recidivism Program Selection Committee conducted a series
of chart review sessions. In these sessions, patients who were identified as being at risk
had their health records reviewed by the multi-disciplinary selection committee. The
committee assessed the patients’ validity for being admitted on the program. Replicated
from the recidivism program, in total, the selection committee reviewed 542 patient
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records. 298 of these were admitted into the recidivism program (N = 298 patients)
(Ketcham, et al., 2014). These 298 patients were tracked for twelve month periods
following the intervention and the number of visits made to the emergency department
were recorded. From there, the head practitioner of the recidivism program created a
spreadsheet with the count data of visits made in the 12-months post-intervention.
This is where I was brought onto the project. As part of my thesis, I utilized
findings given to me from the practitioners leading the recidivism program, which
primarily focused on cohort averages. This thesis project was submitted to the UNM
Office of IRB, where it was categorized as non-human subjects research using secondary
data (see Appendix). From there, I added additional analysis looking at individual results,
aspects of the cohorts, and expanded the data to examine the cohorts that possessed 24
months’ worth of data. I examined these results and compared to the number of
emergency department visits that were made by the particular patient in the twelve-month
period prior to the intervention. This led to the creation of two metrics, 12-month
variance, and 24-month variance. To create this data, the number of visits prior to the
intervention was subtracted from the number of visits following the intervention. This
would result in a reduction of visits having a negative number, which would represent the
number by which the patients decreased their visits.
Hypothesis: A PDMP will reduce the number of unnecessary visits to a hospital’s
emergency department.
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Results

In a chart review session, the committee was able to determine the cost of an
average emergency department visit by one of these patients determined to be at-risk. To
find this number the committee took a random sample of 105 emergency department
visits made by an individual within this population, and averaged the operating costs of
those visits. It was found the average operating cost for one of these visits was $924
(Ketcham, et al., 2014).
Pre-Intervention
The earlier cohorts had higher visit rates than the later cohorts (Table 1a). The
selection committee elected to forgo random selection of patients who were identified as
at-risk. Instead, the committee elected to focus on the patients who were in the upper
threshold of visits at the onset of the recidivism program. Because of this, each of the first
four cohorts had an average visit rate that was equal to or greater than eighteen visits per
patient (Table 1a). After these first initial cohorts, the remaining thirteen cohorts had
visits rates that did not exceed fifteen visits per patient (Table 1a). The average cohort
consisted of 17.5 patients, who had logged an average of 236.7 total emergency
department visits in the twelve months prior to intervention (Table 1a). The size of the
cohorts ranged from eight patients, to forty-one patients. The cohorts with the highest
number of patients enrolled were the second cohort, which had thirty-eight, and the final
cohort, which had the high of forty-one parents. This can be explained by the committee
selecting the patients that had the highest amount of risk early in the program, and then
attempting to enroll as many high-risk patients as possible at the end. On the other side,
the final cohort had large numbers due to the committee wanting to enroll as many at-risk
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patients as possible prior to the conclusion of the program.
As a whole, the 298 patients made a total number of 4,024 emergency department
visits (Table 1a). The average number of visits in the twelve months prior to being
enrolled in the recidivism program was 13.53, or more than one visit a month.
Post-intervention
There were only 10 patients, or 3 percent of the study, who visited the emergency
department more often post-intervention than in the 12 months prior to being enrolled in
the program (Table 3). Also, there were 5 patients, or 1.5 percent of the population, who
had no difference in the number of visits 12 months pre and post-intervention (Table 3).
This means with 4.5 percent of the population seeing no change or an increase in the
number of emergency department visits, that the recidivism program saw a reduction in
the number of emergency department visits in 95.5 percent of the population (Table 3).
The average number of visits for an individual patient in a twelve-month period
was reduced from 13.5 visits, and a 3.68 standard deviation, to a mean of 4.5 visits a
year, with a 1.3 standard deviation (Table 3). The study used Wilcoxon matched-pairs
test and this resulted in a p-value of .001. The total number of visits to the emergency
room made by these at-risk individuals also saw a large decrease. In the twelve-month
period following being admitted to the program, the population had a 67% reduction in
the number of emergency department visits (Table 1a). The post-intervention period saw
a total of 1,319 visits, compared to 4,024 visits that took place in the period prior to the
intervention, a decrease of 2,705 visits (Table 1a). With the elimination of these
presumably unnecessary 2,705 visits, the health care provider saw great benefits. In
addition to the lessened strain on their processes and employees, there was a significant
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amount of financial resources that were saved as well. As found by the recidivism
program data, an average cost of $924 for visits from patients in this population, it is
estimated the provider was able to avoid $2.5 million in operating costs (Ketcham, et al.,
2014). Also, there was approximately $8.38 million in charges that were avoided by
eliminating the unnecessary opioid seeking visits from the emergency department
(Ketcham, et al., 2014).
There was also information to be found within the cohorts. For example, the first
four cohorts, on average, consisted of patients that had higher visit rates than the rest of
the population enrolled in the recidivism program. However, when running a regression
between the number of visits the cohorts averaged prior to the intervention, and the
number of visits following the intervention, there was no correlation (r-square =.1178;
p=.1775) (Figure 1). However, there was a closer relationship between the number of
patients in a cohort and the number of visits for a cohort (Figure 2). This means the
decision by the committee to take serious offenders in early cohorts, and as many patients
as possible in later cohorts did not result in having a significant difference between
patients. This could also occur due to the high variance found within each cohort,
particularly for the cohorts that were smaller in size
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Discussion

The proposed intervention and strategies of obtaining a population were possible
due to the inherent characteristics of this community and the hospital under evaluation.
For example, this hospital is the main health care provider for an area that covers
hundreds of square miles. This allowed for a consolidation of records, resulting in a
selection process with fewer obstacles. Also, this community possess a unique
demographic and social profile that contributes to the results, while also being difficult to
replicate.
The utilization of the multidisciplinary committee allowed for the proper
identification and definition of the problem, while creating measures and procedures to
measure and evaluate the recidivism program. Because there were no aspects of the
actual healthcare being evaluated, this evaluation was more in line with traditional
product evaluations, rather than one for a service, which the emergency department
provides. However, the decision from the committee to select the patients identified to
have the greatest risk of opioid abuse, and place them in the recidivism program first,
created interesting results. For example, it was seen that there was no correlation between
the cohort number and the number of visits each cohort averaged. This would suggest the
committee’s rough attempt to select the patients identified to have the greatest risk of
opioid abuse could have been done with looking at the number of emergency room visits.
Because of this, the practice of using emergency department visits as a key metric may
not be as valid as the recidivism program assumed. The researcher would like to know
what key metrics were discussed during the selection committee meetings, as they could
provide essential information in the identification of at risk patients. Furthermore, with
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542 patients being nominated for review, predominately as a result of emergency room
visits, and only 298 patients in the study, a 55% rate, the validity of the measure is not
clear. This does not dismiss the importance of using emergency room visits as a key
indicator in future studies, or as a threshold measure for administrators, but suggests the
possibility of underlying variables that may have a higher rate of prediction. Further
studies may want to consider other metrics and determine their validity, in addition to
examining the number of emergency department visits.
This decision also created difficulties in examining the results. Had the cohorts
been created using a simple random sample, they could be compared as equals. This
would allow for the analysis of success of the cohorts to be compared to each other in
regards to when the cohort began. However, with the cohorts not being made equal, the
researcher doesn’t feel comfortable in comparing the success of the cohorts and
extrapolating meaningful data. There are too many variables that come in to play when
the cohorts are not randomized. For example, if the committee was correcting in
assuming the patients chosen first for the program had a higher risk for abuse, it is likely
they had a greater level of addiction than other study members. This could result in the
patient engaging in more at-risk behaviors in order to obtain the drug, resting in a greater
chance of death or arrest, which would eliminate the possibility for an emergency
department visit.
Regardless of the committee’s decision to place a triage or priority on the patients
in the recidivism program with a greater identified risk of abuse, the patients and the
program did yield notable results. With over 95% of the study seeing a decrease in the
number of emergency departments in a twelve-month period, the success of this
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recidivism program should be examined further. In just one year this study was able to
reduce the strain on the emergency department and reduce the financial impact of
unnecessary visits. While not specifically measured, given the literature, it is reasonable
to assume the reduced strain, repeat visitors, unnecessary visits, and instances of doctorshopping, resulted in an improved morale and attitude for the staff of the hospital under
evaluation. The reduction of over 2,700 visits would also lead to improved efficiencies
and improved patient satisfaction, as the providers would able to be more attentive to
patients with more concerning needs.
However, there are factors that could influence the number of visits to the
emergency department that the recidivism program, and this study, fail to account for.
For example, one of the patients had 22 visits in the twelve-month period prior to
intervention, and then recorded only two visits in the year post intervention. While this
would appear to show positive evidence for the success and validity of a recidivism
program, these numbers do not tell the whole story. As previously mentioned, the denial
of a prescription opioid can, at times, lead to the patient engaging in high risk behaviors
in order to obtain the drugs (Fibbi, et al., 2012). This could mean the particular patient
with 22 visits, who knew she would not receive the drugs from the hospital, tries to rob a
house so she can buy the drugs on the street. This leads to the patient being in jail for 10
of the 12 months they were in the recidivism program. While 2 visits over the twelve
months sounds somewhat reasonable, 2 visits in 2 months would exceed the visit
threshold that was the criteria for admittance to the program in the first place. Another
confounding factor that was not addressed was the relocation of patietns to an area where
their visits cannot be tracked by this particular hospital. Because of this, any further
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research should have ways to investigate the behaviors and actions of the patients placed
in the program, in order to ensure the validity of the program on the results.
Also, the recidivism program and PDMP established were concerned with patient
outcomes and expectations, and the overall economic burden placed on the hospital.
However, there are more entities represented in this study. While it is likely the patient
experience will have a positive increase due to less inefficiencies in the system, there was
no examination on the experience of the providers. Any similar studies should also
examine the effect seen on the providers themselves, specifically in terms of task
significance, job autonomy, and job satisfaction.
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Conclusion

The use of prescription opioids has been increasing for a significant period of time.
Also increasing at the same rates, and sometimes more rapidly, are the rates of use,
abuse, and overdoses of these prescription medications. There have been a number of
governmental regulations and warnings from industry leaders, but a reversal of the
increasing numbers does not seem to be in sight. With this, hospitals and health
organizations have created solutions to combat this opioid epidemic themselves. One of
these solutions is the utilization of prescription drug monitoring programs. These can
make the prescription habits of doctors, the consumption behaviors of patients, and the
trends of a region, more readily available and easier to recognize for politicians,
administrators, and the general public.
The implementation of a prescription drug monitoring program is recommended for
hospitals, or providers, experiencing a burden related to the use and abuse of prescription
opioid medications. However, additional factors should be examined, such as arrest
record during time spent in program, self-report surveys on behavior and substance use,
third-party reports, and blood or urine analysis. This recidivism program, and this study,
have laid the groundwork to receiving the complete picture of how a recidivism program
can create positive change, but the issue must be examined further.
While focused on a health issue, this study shows the importance of how a
progressive administrator, or administration, can have a positive impact in various arenas.
Even though it is not always the goal, politicians and government leaders can enact health
policies and initiatives that have positive effects in other arenas as well. Conversely,
programs or initiatives not focused on health care can positively impact the health sector.
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This study showed how an initiative started by a physician and administrator resulted in
the positive impact on the organization’s finances, ability to serve customers (patients),
while also having a positive impact on community health. By analyzing other areas of
high concern, public administrators can preemptively stay ahead of regulations, create
examples for other organizations to follow, and have positive outcomes in many areas of
their organization.
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Tables & Figures
Table 1a – Emergency Department Visitations by Cohorts
Table 1 sorts the cohorts by the date they began (Column 1), and lists the number of
patients in each cohort (Column 2), the number of visits for all member of the cohort
(Column 3), and the average number of visits per patient in each
cohort (Column 4). Also displayed in Table 1a are the number of visits for all members
of the cohort (Column 5) and the average number of visits per patient in each cohort, 12
months after being enrolled in the prescription opioid recidivism program. At the bottom
of Figure 1 is the change seen in the number of visits, and in percentage of visits.

Cohort Date
3/7/12
5/1/12

Number of
Patients
12
38

Baseline Visit
Total
258
684

Baseline Avg Visit Rate
per patient
21.50
18.00

5/15/12
5/22/12
6/19/12

20
18
8

377
343
104

18.85
19.06
13.00

107
121
34

5.35***
6.72***
4.25***

7/2/12
7/15/12

11
8

107
110

10.91
13.75

37
20

3.36***
2.50***

7/23/12
9/5/12
9/14-22/12
10/8/12

15
13
10
16

222
128
116
178

14.80
9.85
11.60
11.07

80
36
55
93

5.33***
2.77***
5.50***
6.20***

11/2/12
11/25-27/12
12/12/12

14
14
22

155
185
274

11.08
13.21
12.45

62
91
104

4.62***
6.50***
4.73***

1/15/13
2/5/13

16
22

190
216

11.88
9.82

60
77

3.75***
3.59***

2/15/13

41

377

9.20

120

2.93***

Totals:

298

4024

13.53

1319

4.50

Change
% change

n/a
n/a

n/a
n/a

n/a
n/a

-2,705
-67

-9.03
-33.00

*** p-value <0.001

Total Visits in Visit Rate after 1
1st year
year
46
3.83***
176
4.63***
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Table 1b
Similarly to Table 1a, Table 1b shows the number of patients in a cohort (Column
1), ), the number of visits for all member of the cohort (Column 3), and the average
number of visits per patient in each cohort (Column 4). Also displayed in Table 1b are
the number of visits for all members of the cohort (Column 5) and the average number of
visits per patient in each cohort, in the 12-24 months after being enrolled in the
prescription opioid recidivism program. At the bottom of Table 1b is the change seen in
the number of visits, and in percentage of visits.

Cohort 1
Cohort 2
Totals:
Change
% Change

Number of
Patients
12

Baseline Visit
Total
258

Baseline Avg Visit Rate
per patient
21.50

Total Visits in
2nd Year
16

Rate in
2nd year
2.875

38
50
n/a
n/a

684
471
n/a
n/a

18.00
18.84
n/a
n/a

140
156
-315
-33

3.68
3.12
15.72
-16.5
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Table 2
Table 2 depicts the amount and percentage of patients enrolled in the prescription
opioid recidivism program who saw a decrease in their number of visits in the 12 month
period after enrollment (Column 2 and 3, respectively). Columns 4 and 5 have the
amount and percentage of patients who saw no change in their number of visits, while
Columns 6 and 7 show the same information but for patients who increased their number
of visits to the emergency department after enrollment in the recidivism program.

Decrease

Decrease
%

No
change

No
change
%

n/a

Increase

Increase
%

Preintervention

n/a

n/a

12 months

283

94.5

5

1.5

10

3

24 months

49

100

0

0

0

0
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Table 3
This table shows the average amount of visits in the pre-intervention process, the
standard deviation of these visits, and compares it to the results complied after all
participants had completed 12 months in the recidivism program.

Time Period

Average number

Standard

of visits

Deviation

13.5

3.68

n/a

4.5

1.3

n/a

Variance

-9

-2.38

n/a

Total

n/a

n/a

.001

12 months pre-

P-value

intervention
12 months postintervention
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Figure 1
This graph shows the relationship between the number of visits pre-intervention (xaxis) and post-intervention (y-axis).
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Figure 2
This graph shows the relationship between the number of patients in a given cohort
(x-axis), and the total number of visits for that cohort (y-axis)
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